Ken Maes

Scientist genetic profiling of cancer

Belgium

Research Interests

Explore related searches

Professors in Belgium Professors in Immunology Immunology professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ken Maes is a Scientist at the Universitair Ziekenhuis Brussel Centrum voor Medische Genetica in Belgium. His research focuses on genetic profiling of cancer, particularly in acute myeloid leukemia and multiple myeloma. Recent articles highlight his work on therapeutic targeting of myeloid-derived suppressor cells and innovative approaches to treatment using RNA sequencing and epigenetic modifiers.

Articles (12)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Collaborators (28)

Anke Maes

Vrije Universiteit Brussel

BELGIUM

Ken Maes

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma

Peripheral precocious puberty in Li-Fraumeni syndrome

Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers

Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.

Genetic profiling of human bone marrow mesenchymal stromal cells after in vitro expansion in clinical grade human platelet lysate

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor–mediated cell death

Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.

Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer.

Collaborators (28)

Anke Maes

Willem Staels

Niels Vandewalle

Kirsten De Ridder

Cleo Goyvaerts

Catarina Xavier

Yannick De Vlaeminck

Jesse Vanbesien

Tony Lahoutte

Ann Massie

Catharina Muylaert

Inge Gies

Robin Maximilian Awad

Ann De Becker

Rong Fan

Frederik Hes

Lien De Beck

Quentin Lecocq

Philippe Giron

Gamze Ates

Kaat Wilgenhof

Philip Vlummens

Jerome Moreaux

Robbe Heestermans

Kim De Veirman

Stefaan Verhulst

Emma Verheye

Elke De Bruyne

Make your next move.